



**LXT-801: A FIRST-IN-CLASS  
BISPECIFIC AGONIST TO  
TREAT WOUNDS**

**Murali K Addepalli**  
*Co-founder & CSO*

# ABOUT LEXTRO LABS




- Founded by Srinivas Akkina MBA and Murali Addepalli Ph.D. in 2022 at Genome Valley, Hyderabad, India
- Lextro Labs has developed Immune Modulation & Cytotoxicity (ImCy) platform
- ImCy has lead to generation of novel first-in-class & best-in-class therapeutic molecules

ASSET	INDICATION	STAGE			
		RESEARCH	PRECLINICAL	IND	
*LXT-801 (D)	Diabetic (T1 & T2) wounds	██████████	██████████	Q4, 2024	Clinics
*LXT-801 (B)	Burn wounds	██████████	██████████	Q4, 2024	
*LXT-801 (I)	Immune Suppressive Wounds (Transplantation, Sepsis)	██████████	██████████	Q1, 2025	
LXT-108	Metastatic Breast & Lung Cancer	██████████	██████████	Q2, 2025	
LXT-901	Immune Refractory Cancers	██████	██████		
*Patent Pending					

# IMPAIRED WOUND HEALING IN DIABETIC PATIENTS



- As on 2021, >537 M diabetic patients
  - ~88 M diabetic wound related amputations
- Pathophysiology consists of microvascular diseases
- Dysfunctional innate & adaptive immune cells
- Enhanced immune-suppression with antibiotic therapy



LEXTRO BELIEVES UNMET MEDICAL  
NEED IN RESTORING IMMUNE  
FUNCTIONALITY OF WOUND HEALING

[doi.org/10.1016/j.biopha.2019.108615](https://doi.org/10.1016/j.biopha.2019.108615)


DOI 10.7759/cureus.27180

doi: 10.1002/edm2.298

# SALIENT FEATURES OF LXT-801




- Glycoprotein of ~ 36 KDa
- Proliferates and Migrates
  - Innate & adaptive immune cells
  - keratinocytes, fibroblasts etc.,
- Controlled PK Profile by Formulation
  - Intradermal / Subcutaneous
  - Topical
  - Patches
- Stable and Scalable



Main Peak  
(87% of the  
total area)



RP-HPLC profile of a purified variant of LXT 801 protein



90 % purity  
by SDS PAGE

Lane M<sub>1</sub>: Marker  
Lane R: Reducing condition  
Lane NR: Non-Reducing condition

# LXT-801 STIMULATES WOUND HEALING PATHWAYS






pSTAT5 in Lymphocytes	Positive control	LXT 801 E	LXT 801 E1	LXT 801 E6	LXT 801 D2
EC50	0.064	0.073	0.043	0.021	0.080

Phosphorylated ERK1/2	LXT 801 E	LXT 801 E1	LXT 801 E6	LXT 801 D2
EC50	12.72	3.991	0.9861	1.081

LXT-801 Phosphorylates STAT5 & ERK1/2 in Human PBMC & Epithelial cells

# LXT-801 TREATS DIABETIC WOUNDS IN T2DM RATS



Statistical significance calculated by unpaired t-test  
 \* = Compared with vehicle treatment  
 ^ = Compared with Naive  
 \* = P<0.05, \*\* = P<0.01 & \*\*\*\* = P<0.001

- Significant (P<0.05) efficacy over vehicle in
  - Wound Healing
  - Increasing Spleen Weights
- Histopathological Observations (data not shown)
  - Improved Vasculature
  - Enhanced Collagen Deposition
  - Increased Fibroblasts Proliferation

# LEXTRO TEAM



**SRINIVAS AKKINA**

MBA  
*Co-founder & MD*



**MURALI ADDEPALLI**

PhD  
*Co-founder & CSO*



**TEJ KUMAR MADINENI**

MSc  
*Associate Vice President*



**DR. NARASIMHULU SIMMA**

PhD  
*Sr. Scientist*



**SHALINI KOLARKAR**

MSc  
*Scientist*

Lextro Labs is seeking Joint Ventures and Investments. Please reach out at [murali.a@lextrobio.com](mailto:murali.a@lextrobio.com)



T H A N K Y O U

*Advanced Therapeutics To Rejuvenate Life*

**Lextro Labs Pvt. Ltd.**

2nd Floor, Building #189, Synergy Square 1  
Genome Valley, Hyderabad - 500 078, India